Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression

J Biol Chem. 2007 Apr 13;282(15):11329-38. doi: 10.1074/jbc.M611526200. Epub 2007 Feb 15.

Abstract

Beta-arrestin1, which regulates many aspects of seven transmembrane receptor (7TMR) biology, has also been shown to serve as an adaptor, which brings Mdm2, an E3 ubiquitin ligase to the insulin-like growth factor-1 receptor (IGF-1R), leading to its proteasome-dependent destruction. Here we demonstrate that IGF-1R stimulation also leads to ubiquitination of beta-arrestin1, which regulates vesicular trafficking and activation of ERK1/2. This beta-arrestin1-dependent ERK activity can occur even when the classical tyrosine kinase signaling is impaired. siRNA-mediated suppression of beta-arrestin1 in human melanoma cells ablates IGF-1-stimulated ERK and prolongs the G1 phase of the cell cycle. These data suggest that beta-arrestin-dependent ERK signaling by the IGF-1R regulates cell cycle progression and may thus be an important regulator of the growth of normal and malignant cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arrestins / pharmacology*
  • Cell Cycle*
  • Cell Line
  • Enzyme Activation / drug effects
  • Humans
  • Insulin-Like Growth Factor I / pharmacology
  • Mice
  • Mitogen-Activated Protein Kinase 1 / metabolism*
  • Mitogen-Activated Protein Kinase 3 / metabolism*
  • Mutation / genetics
  • Phosphorylation
  • Protein Transport
  • Proto-Oncogene Proteins c-mdm2 / metabolism*
  • Receptor, IGF Type 1 / genetics
  • Receptor, IGF Type 1 / metabolism*
  • Signal Transduction
  • Ubiquitin / metabolism
  • beta-Arrestins

Substances

  • Arrestins
  • Ubiquitin
  • beta-Arrestins
  • Insulin-Like Growth Factor I
  • Proto-Oncogene Proteins c-mdm2
  • Receptor, IGF Type 1
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3